MSC Therapeutics in Chronic Inflammation

Current Stem Cell Reports

Volumn 2, Issue 2, 2016, Pages 168-173

  Sargent, Alex ^a   Miller, Robert H ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

EAE; Immune suppression; Mesenchymal stem cells; Multiple sclerosis

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR;

ASTROCYTE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC INFLAMMATION; DEMYELINATION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SCLEROSIS; NEURAL STEM CELL; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 85038811735     PISSN: None     EISSN: 21987866     Source Type: Journal    
DOI: 10.1007/s40778-016-0044-6     Document Type: Review

References (41)

1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–7.
2. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3(3):301–13. doi:10.1016/j.stem.2008.07.003.
3. Caplan AI. All MSCs are pericytes? Cell Stem Cell. 2008;3(3):229–30. doi:10.1016/j.stem.2008.08.008.
4. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7. doi:10.1080/14653240600855905.
5. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11–5. doi:10.1016/j.stem.2011.06.008.
6. Dimarino AM, Caplan AI, Bonfield TL. Mesenchymal stem cells in tissue repair. Front Immunol. 2013;4:201. doi:10.3389/fimmu.2013.00201.
7. Patel SA, Sherman L, Munoz J, Rameshwar P. Immunological properties of mesenchymal stem cells and clinical implications. Arch Immunol Ther Exp (Warsz). 2008;56(1):1–8. doi:10.1007/s00005-008-0001-x.
8. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579–86. doi:10.1016/S0140-6736(08)60690-X.
9. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276(5309):71–4.
10. Caplan AI, Bruder SP. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol Med. 2001;7(6):259–64.
11. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19. doi:10.1056/NEJMra100496510.7748/phc2011.11.21.9.29.c8797.
12. Panayi GS, Corrigall VM, Pitzalis C. Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am. 2001;27(2):317–34.
13. Pitzalis C, Kingsley G, Murphy J, Panayi G. Abnormal distribution of the helper-inducer and suppressor-inducer T-lymphocyte subsets in the rheumatoid joint. Clin Immunol Immunopathol. 1987;45(2):252–8.
14. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 2008;223:7–19. doi:10.1111/j.1600-065X.2008.00626.x.
15. Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katasikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 2008;58(2 Suppl):S92–101. doi:10.1002/art.23362.
16. Kavanaugh AF. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998;24(3):593–614.
17. Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol Suppl. 1999;57:7–15.
18. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther. 2011;2(4):34. doi:10.1186/scrt75.
19. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum. 2009;60(4):1006–19. doi:10.1002/art.24405.
20. Lopez-Santalla M, Mancheno-Corvo P, Menta R, Lopez-Belmonte J, DelaRosa O, Bueren JA, et al. Human adipose-derived mesenchymal stem cells modulate experimental autoimmune arthritis by modifying early adaptive T cell responses. Stem Cells. 2015;33(12):3493–503. doi:10.1002/stem.2113. This study showed that MSCs improve recovery in the rodent CIA model of RA by reducing the number of pathogenic Th1-cells and increasing the number of regulatory T-cells.
21. Gu J, Gu W, Lin C, Gu H, Wu W, Yin J, et al. Human umbilical cord mesenchymal stem cells improve the immune-associated inflammatory and prothrombotic state in collagen type—induced arthritic rats. Mol Med Rep. 2015;12(5):7463–70. doi:10.3892/mmr.2015.4394.
22. Tanaka Y. Human mesenchymal stem cells as a tool for joint repair in rheumatoid arthritis. Clin Exp Rheumatol. 2015;33(4 Suppl 92):S58–62.
23. Zhang X, Yamaoka K, Sonomoto K, Kaneko H, Satake M, Yamamoto Y, et al. Local delivery of mesenchymal stem cells with poly-lactic-co-glycolic acid nano-fiber scaffold suppress arthritis in rats. PLoS One. 2014;9(12), e114621. doi:10.1371/journal.pone.0114621. This study used a nanofiber scaffold to effectively transplant and retain MSCs to an inflamed joint of arthric rats, where they could effectively suppress inflammation and bone degradation.
24. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol. 2001;2(9):762–4. doi:10.1038/ni0901-762.
25. Prineas JW. The neuropathology of multiple sclerosis. In: Koestier JC, editor. Handbook of clinical neurology. Amsterdam: Elsevier; 1985.
26. Furlan R, Cuomo C, Martino G. Animal models of multiple sclerosis. Methods Mol Biol. 2009;549:157–73. doi:10.1007/978-1-60327-931-4_11.
27. Gerdoni E, Gallo B, Casazza S, Musio S, Bonanni I, Pedemonte E, et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol. 2007;61(3):219–27.
28. Uccelli A, Milanese M, Principato MC, Morando S, Bonifacino T, Vergani L, et al. Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. Mol Med. 2012;18:794–804. doi:10.2119/molmed.2011.00498.
29. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005;106(5):1755–61. doi:10.1182/blood-2005-04-1496.
30. Tyndall A, Walker UA, Cope A, Dazzi F, De Bari C, Fibbe W, et al. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther. 2007;9(1):301. doi:10.1186/ar2103.
31. Bai L, Lennon DP, Caplan AI, DeChant A, Hecker J, Kranso J, et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat Neurosci. 2012;15(6):862–70. doi:10.1038/nn.3109. This study showed that MSC-induced recovery in EAE is mediated by factors like hepatocyte growth factor (HGF) that are secreted from MSCs.
32. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. 2009. doi:10.1002/glia.20841.
33. Bai L, Caplan A, Lennon D, Miller RH. Human mesenchymal stem cells signals regulate neural stem cell fate. Neurochem Res. 2007;32(2):353–62. doi:10.1007/s11064-006-9212-x.
34. Fox JM, Chamberlain G, Ashton BA, Middleton J. Recent advances into the understanding of mesenchymal stem cell trafficking. Br J Haematol. 2007;137(6):491–502. doi:10.1111/j.1365-2141.2007.06610.x.
35. Jadasz JJ, Kremer D, Göttle P, Tzekova N, Domke J, Rivera FJ, et al. Mesenchymal stem cell conditioning promotes rat oligodendroglial cell maturation. PLoS One. 2013;8(8), e71814. doi:10.1371/journal.pone.0071814.
36. Lanza C, Morando S, Voci A, Canesi L, Principato MC, Serpero LD, et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem. 2009;110(5):1674–84. doi:10.1111/j.1471-4159.2009.06268.x.
37. Benkhoucha M, Santiago-Raber ML, Schneiter G, Chofflon M, Funakoshi H, Nakamura T, et al. Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2010;107(14):6424–9. doi:10.1073/pnas.0912437107.
38. El-Akabawy G, Rashed LA. Beneficial effects of bone marrow-derived mesenchymal stem cell transplantation in a non-immune model of demyelination. Ann Anat. 2015;198:11–20. doi:10.1016/j.aanat.2014.12.002.
39. Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11(2):150–6. doi:10.1016/S1474-4422(11)70305-2.
40. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;67(10):1187–94. doi:10.1001/archneurol.2010.248.
41. Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells as treatment for MS—progress to date. Mult Scler. 2013;19(5):515–9. doi:10.1177/1352458512464686.